Last reviewed · How we verify
Bevespi
Bevespi is a marketed drug developed by the University of Miami, currently positioned in the respiratory therapy segment. The key composition patent for Bevespi is set to expire in 2028, providing a period of exclusivity that supports its market presence. The primary risk is the lack of disclosed revenue and key trial results, which may limit investor confidence and competitive positioning.
At a glance
| Generic name | Bevespi |
|---|---|
| Sponsor | University of Miami |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD (PHASE2)
- The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD (PHASE4)
- Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease (NA)
- Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI (PHASE2, PHASE3)
- The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevespi CI brief — competitive landscape report
- Bevespi updates RSS · CI watch RSS
- University of Miami portfolio CI